Bavarian Nordic's Share Buy-Back Program Gains Momentum
Share Buy-Back Program Overview
Bavarian Nordic A/S (Copenhagen: BAVA) is currently executing a share buy-back program to reinforce its commitment to shareholders. The program, which was initiated on January 9, involves repurchasing shares for up to DKK 150 million until February 5. This initiative reflects the company's confidence in its value and future outlook.
Recent Transactions
As of the latest report, the company has successfully completed several transactions as part of the buy-back initiative. Since the previous update on January 20, the following purchases were made:
Transaction Details
As of January 20, 2025, the accumulated purchases stood at 358,000 shares, with an average purchase price of DKK 197.78, totaling DKK 70,806,380. Subsequently, shares were acquired on various dates:
- January 20: 52,000 shares at an average price of DKK 195.60, totaling DKK 10,171,200.
- January 21: 40,000 shares at an average price of DKK 197.16, translating to DKK 7,886,400.
- January 22: 50,000 shares were bought at DKK 198.70, amounting to DKK 9,935,000.
- January 23: Another purchase of 50,000 shares at an average price of DKK 197.78, totaling DKK 9,889,000.
- January 24: 38,000 shares purchased at DKK 201.50 for a total of DKK 7,657,000.
Overall, up to January 24, 2025, Bavarian Nordic has purchased a total of 588,000 shares through this program, at an average price of DKK 197.87, summing to DKK 116,344,980.
Impact on Treasury Shares
After executing these transactions, Bavarian Nordic now holds a total of 872,235 treasury shares, representing 1.11% of the company's share capital. This increase in treasury stock is significant as it underscores the company's strategic direction and investment in its own equity.
Company Profile
Bavarian Nordic is recognized as a leading global vaccine company dedicated to enhancing public health through innovative vaccine solutions. The company is noted for being a key supplier of vaccines targeting mpox and smallpox, aimed at improving health preparedness among governmental entities globally. Furthermore, Bavarian Nordic boasts a diverse portfolio of travel vaccines, catering to various public health needs.
Contact Information
For any inquiries, investors can reach out to:
Rolf Sass Sørensen
Vice President Investor Relations
Tel: +45 61 77 47 43
In the US, Graham Morrell from Paddock Circle Advisors is available at +1 781 686 9600.
Frequently Asked Questions
What is the purpose of the share buy-back program?
The program aims to enhance shareholder value by repurchasing shares in the market, reflecting the company's confidence in its future.
How many shares has Bavarian Nordic repurchased?
As of January 24, 2025, Bavarian Nordic has repurchased a total of 588,000 shares under the buy-back program.
What percentage of shares does Bavarian Nordic hold in treasury?
Currently, the company holds 872,235 treasury shares, which equates to 1.11% of its share capital.
How does the buy-back program comply with regulations?
The program is executed in compliance with Regulation (EU) No. 596/2014, ensuring transparency and adherence to market regulations.
Who can I contact for investor relations inquiries?
Investors can contact Rolf Sass Sørensen at +45 61 77 47 43 for information related to investor relations.
About The Author
Contact Thomas Cooper here.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.